News

A team of U.S. researchers have identified two proteins in the lab — PIKFYVE and SYF2 — that may each be a useful therapeutic target for treating amyotrophic lateral sclerosis (ALS). Their findings on these potential molecular targets were published in a pair of studies earlier this month. “Our…

A group of experts, led by scientists from the National Institute of Neurological Disorders and Stroke (NINDS), has published a set of strategic priorities for the amyotrophic lateral sclerosis (ALS) community that are expected to guide future research funding. The goals include better understanding the biology underlying ALS, finding…

Significant delays in the diagnosis of amyotrophic lateral sclerosis (ALS) were revealed by a new large-scale analysis of real-world patient records using artificial intelligence (AI). In fact, the median time from the first symptom to an ALS diagnosis was 11 months for these patients. Similar delays were seen regardless…

Human motor neurons rely on a specialized molecular architecture to help support their large size, which may partially explain why they are more vulnerable than other nerve cells to damage in amyotrophic lateral sclerosis (ALS). That’s according to the study, “A cellular taxonomy of the adult…

Seelos Therapeutics has finished enrolling patients in its Phase 2/3 clinical trial of SLS-005 to treat amyotrophic lateral sclerosis (ALS), the company announced. The ongoing trial (NCT05136885) recruited 160 patients with familial and sporadic ALS, and top-line results are expected by the second half of…

A small Phase 2 clinical trial is evaluating the safety and tolerability of investigational treatment candidate EPI-589 in adults with amyotrophic lateral sclerosis (ALS). The EPIC-ALS trial (jRCT2061210031), being conducted in Japan, will also assess exploratory effectiveness outcomes after six months of treatment. Data collection began in September…

A wearable robotic device that helps lift the shoulders to support arm movements can make it easier for people with amyotrophic lateral sclerosis (ALS) to do daily tasks, a new study reports. Using the lightweight device — now a fabric-based robot prototype — led to significant improvements in upper…

The Phase 2b trial testing PrimeC in people with amyotrophic lateral sclerosis (ALS) will no longer enroll patients in the U.S., its maker NeuroSense Therapeutics has announced. Meanwhile, the company has been given the green light from regulatory agencies in Germany and Canada to enroll new participants,…

AC Immune has been awarded more than $500,000 in nonprofit grants by the Michael J. Fox Foundation (MJFF) and the Target ALS Foundation to support its programs to detect abnormal forms of the TDP-43 protein via imaging scans and fluid samples. “It is an honor to have…

A Phase 1/2 clinical trial testing the investigational imaging agent 18F-OP-801 in healthy volunteers and people with amyotrophic lateral sclerosis (ALS) has enrolled its first patient. Ashvattha Therapeutics‘ agent is designed to detect inflammation in imaging exams like positron emission tomography (PET) or MRI scans. This is possible…